glp 1 efficacy comparison Changes in weight with GLP-1 RAs in head-to-head clinical studies. *p < GLP-1 Medications for Weight Loss:

Consequently, GIP and GLP-1 receptor agonists exhibit complementary and potentially synergistic actions, suggesting that their combined administration may further enhance glucose regulation and support weight reduction

by doing so you will then be able to administer ipamorelin safely and effectively

However, IL Medicaid explicitly excludes weight-loss GLP-1s so Zepbound and Wegovy are not covered for obesity under IL Medicaid

While they produce modest LDL cholesterol reductions of 2-10%, statins remain first-line therapy for patients requiring significant lipid lowering, and GLP-1 agents work best as complementary therapy alongside statins